Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
Eur J Gastroenterol Hepatol
    October 2022
  1. YIBIRIN M, Hosry J, Yepez Guevara E, Granwehr BP, et al
    High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2022;34:1098-1101.
    >> Share

    May 2022
  2. DOFFOEL M, Tripon S, Ernwein F, Chaffraix F, et al
    Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
    Eur J Gastroenterol Hepatol. 2022;34:560-566.
    >> Share

    March 2022
  3. TAHTASAKAL CA, Oncul A, Sevgi DY, Demirbas D, et al
    Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
    Eur J Gastroenterol Hepatol. 2022;34:308-315.
    >> Share

    February 2022
  4. TOYODA H, Yasuda S, Shiota S, Kumada T, et al
    Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97088.
    >> Share

    December 2021
  5. DOFFOEL M, Ernwein F, Chaffraix F, Haumesser L, et al
    Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97102.
    >> Share

  6. NG A
    Underdiagnosis of hepatitis C in the community: do not forget vulnerable populations.
    Eur J Gastroenterol Hepatol. 2021;33.
    >> Share

  7. NG A
    Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C.
    Eur J Gastroenterol Hepatol. 2021;33.
    >> Share

  8. BASSO M, Zago D, Pozzetto I, Parisi SG, et al
    Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Eur J Gastroenterol Hepatol. 2021;33.
    >> Share

    September 2021
  9. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    >> Share

    July 2021
  10. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    >> Share

  11. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    >> Share

    April 2021
  12. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    >> Share

  13. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    >> Share

  14. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    >> Share

    March 2021
  15. SERWAH MA, Omar SA, Khedr MS, Abdel-Hamid AES, et al
    Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97270.
    >> Share

    February 2021
  16. SAHIN M, Sucu P, Serin E, Yetim A, et al
    Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C.
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97302.
    >> Share

  17. SAUD LRC, Chagas AL, Maccali C, Pinto PVA, et al
    Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior?
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97300.
    >> Share

    January 2021
  18. EL-NAHAAS SM, Rady NH, Malek S, Serag K, et al
    Changes in serum interferon-gamma-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97309.
    >> Share

  19. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    >> Share

  20. YILMAZ B, Kayadibi H, Yeniova AO, Koseoglu H, et al
    The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    >> Share

  21. PESTANA NF, Equi CMA, Gomes CP, Cardoso AC, et al
    Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    >> Share

    November 2020
  22. LASHEN SA, Metawea MI, Shaaban A
    Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002015.
    >> Share

  23. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018).
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002012.
    >> Share

  24. LITHY RM, Elbaz T, H Abdelmaksoud A, M Nabil M, et al
    Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001972.
    >> Share

  25. RUIZ I, Fourati S, Ahmed-Belkacem A, Rodriguez C, et al
    Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000002003.
    >> Share

    October 2020
  26. OMRAN M, Fouda M, Abdelwahab AO, Nabeel MM, et al
    P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001962.
    >> Share

    September 2020
  27. STEIN K, Stoehr A, Klinker H, Teuber G, et al
    Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001923.
    >> Share

    August 2020
  28. ABDO M, Rabiee A, Abdellatif Z, Abdel Alem S, et al
    Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001903.
    >> Share

  29. NUMAO H, Shimaya K, Kakuta A, Shibutani K, et al
    The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001887.
    >> Share

  30. BEYAN C, Beyan E
    Mean platelet volume to platelet ratio may not be reliable to determine the severity of fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:1067.
    >> Share

  31. ELSADEK HM, Abdelbaser ES, Emara MH, Soliman HH, et al
    Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Eur J Gastroenterol Hepatol. 2020;32:1046-1053.
    >> Share

    July 2020
  32. GUAN X, Xing F, Li Y
    Alcohol consumption increases the incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis but not in patients with hepatitis C cirrhosis.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001837.
    >> Share

  33. GARRIDO-ESTEPA M, Latasa P, Flores-Herrera J, Garcia Comas L, et al
    Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001841.
    >> Share

  34. CHEN SH, Huang CL, Chiang IP, Chang TC, et al
    Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001833.
    >> Share

  35. MCPHAIL J, Sims OT, Guo Y, Wooten D, et al
    Fibrosis improvement in patients with HCV treated with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.
    >> Share

    June 2020
  36. ABDEL MOEZ AT, El Hawary YA, Al Balakosy AM
    Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients?
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001790.
    >> Share

  37. DA BL, Lourdusamy V, Kushner T, Dieterich D, et al
    Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001786.
    >> Share

    May 2020
  38. QIU LX, Liu YL, Lin W, Liu YR, et al
    Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001749.
    >> Share

  39. TANOGLU A
    Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2020;32:664-665.
    >> Share

    April 2020
  40. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    >> Share

    March 2020
  41. GONZALEZ-COLOMINAS E, Batlle M, Monge-Escartin I, Duran X, et al
    Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response.
    Eur J Gastroenterol Hepatol. 2020 Mar 16. doi: 10.1097/MEG.0000000000001714.
    >> Share

  42. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:378-385.
    >> Share

    February 2020
  43. PERISETTI A, Laoveeravat P, Inamdar S, Tharian B, et al
    Hepatitis E virus infection in liver transplant recipients: a descriptive literature review.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001682.
    >> Share

    January 2020
  44. ABDELSAMEEA E, Alsebaey A, Abdel-Razek W, Ehsan N, et al
    Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C.
    Eur J Gastroenterol Hepatol. 2020 Jan 15. doi: 10.1097/MEG.0000000000001672.
    >> Share

    December 2019
  45. HASSANIN TM, Abdelraheem EM, Abdelhameed S, Abdelrazik M, et al
    Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001647.
    >> Share

  46. RAMACHANDRAN J, Kaambwa B, Muller K, Haridy J, et al
    Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001659.
    >> Share

  47. LIONS C, Laroche H, Zaegel-Faucher O, Ressiot E, et al
    Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001640.
    >> Share

  48. DARWEESH SK, Yosry A, Salah M, Zayed N, et al
    Acoustic radiation forced impulse-based splenic prediction model using data mining for the noninvasive prediction of esophageal varices in hepatitis C virus advanced fibrosis.
    Eur J Gastroenterol Hepatol. 2019;31:1533-1539.
    >> Share

    November 2019
  49. SHOUSHA HI, Saad Y, Saleh DA, Dabes H, et al
    Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001612.
    >> Share

  50. TOSON EA, Shiha GE, El-Sharkawy AM, El-Mezayen HA, et al
    Diagnostic performance of extrinsic apoptosis pathway in hepatitis C virus patients: apoptosis fibrosis crosstalk.
    Eur J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1097/MEG.0000000000001603.
    >> Share

  51. GOZDAS HT, Ince N
    Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001599.
    >> Share

  52. SLIEM HA, Salem AS, Hussien WM, El Sayed HRA, et al
    Arterial wall structural changes in noncirrhotic chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019;31:1432-1438.
    >> Share

  53. WIEGAND J, Buggisch P, Mauss S, Boeker KHW, et al
    Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Eur J Gastroenterol Hepatol. 2019;31:1424-1431.
    >> Share

    October 2019
  54. EL-KHAYAT H, Kamal EM, Mahmoud H, Gomaa A, et al
    Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001581.
    >> Share

  55. HEIL J, Soufidi K, Stals F, Frantzen H, et al
    Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001593.
    >> Share

  56. TACHI Y, Hirai T, Kojima Y, Tachino H, et al
    Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001539.
    >> Share

    September 2019
  57. ABBAS OM, Khalifa KAE, Makhlouf MM, Osman NF, et al
    Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001547.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016